524 A phase 2, multi-arm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors

• Vivek Subbiah,
• Shivaani Kummar,
• Ulka Vaishampayan,
• Mark Chao,
• Sandip Patel,
• James Strauss,
• Lanjia Lin,
• Sonam Puri,
• Giri Ramsingh

Affiliations

Vivek Subbiah

Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Shivaani Kummar

Aff39 grid.168010.e0000000419368956Stanford University School of Medicine Stanford CA USA

Ulka Vaishampayan

10 Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

Mark Chao

Aff532 grid.168010.e0000000419368956Institute for Stem Cell Biology and Regenerative Medicine, Forty Seven, Inc.Stanford University School of Medicine Palo Alto CA USA

Sandip Patel

3University of California at San Diego, La Jolla, California, USA

James Strauss

2Mary Crowley Cancer Research Center, Dallas, TX, USA

Lanjia Lin

13Gilead Sciences, Foster City, USA

Sonam Puri

3Huntsman Cancer Center at the University of Utah, Salt Lake City, UT, USA, Salt Lake City, UT, USA

Giri Ramsingh

4Gilead Sciences, Inc., Foster City, CA, USA, Foster City, CA, USA